Loading clinical trials...
Loading clinical trials...
An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STX209 (Arbaclofen) in Subjects With Autism Spectrum Disorders
Conditions
Interventions
STX209 (arbaclofen)
Locations
25
United States
Southwest Autism Research & Resource Center
Phoenix, Arizona, United States
University of California-Los Angeles Neuropsychiatric Institute
Los Angeles, California, United States
UCDavis M.I.N.D Insitute
Sacramento, California, United States
Pharmax Research Clinic
Miami, Florida, United States
Lake Mary Pediatrics
Orange City, Florida, United States
Institute for Behavioral Medicine
Smyrna, Georgia, United States
Start Date
November 1, 2011
Primary Completion Date
July 1, 2013
Completion Date
July 1, 2013
Last Updated
July 31, 2013
NCT07076264
NCT01031407
NCT01250938
NCT02028247
NCT01908686
NCT02903030
Lead Sponsor
Seaside Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions